(0.03%) 5 471.19 points
(0.08%) 39 145 points
(0.36%) 17 781 points
(-0.01%) $80.82
(-3.66%) $2.66
(-0.80%) $2 312.10
(0.18%) $28.92
(3.49%) $1 020.80
(0.27%) $0.936
(0.68%) $10.68
(0.42%) $0.792
(-0.27%) $87.25
Live Chart Being Loaded With Signals
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors...
Stats | |
---|---|
今日成交量 | 2.48M |
平均成交量 | 3.98M |
市值 | 726 089 |
EPS | $-0.110 ( Q2 | 2023-08-10 ) |
下一个收益日期 | ( $0 ) 2024-08-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-0.0182 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.00900 (230.77%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-09-09 | Perkins Adelene Q | Buy | 768 133 | Common Stock |
2023-09-12 | Perkins Adelene Q | Sell | 410 196 | Common Stock |
2023-09-09 | Perkins Adelene Q | Sell | 768 133 | Restricted Stock Unit |
2022-08-02 | Peluso Stephane | Buy | 14 994 | Common Stock |
2022-08-02 | Peluso Stephane | Sell | 50 000 | Restricted Stock Unit |
INSIDER POWER |
---|
-20.62 |
Last 96 transactions |
Buy: 10 433 668 | Sell: 9 549 867 |
音量 相关性
Infinity Pharmaceuticals 相关性 - 货币/商品
Infinity Pharmaceuticals 财务报表
Annual | 2022 |
营收: | $2.59M |
毛利润: | $1.03M (39.72 %) |
EPS: | $-0.480 |
FY | 2022 |
营收: | $2.59M |
毛利润: | $1.03M (39.72 %) |
EPS: | $-0.480 |
FY | 2021 |
营收: | $1.86M |
毛利润: | $738 000 (39.72 %) |
EPS: | $-0.530 |
FY | 2020 |
营收: | $1.72M |
毛利润: | $682 000 (39.67 %) |
EPS: | $-0.680 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Infinity Pharmaceuticals
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Cambridge, Massachusetts.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。